The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the addition of acalabrutinib (Calquence) to bendamustine and rituximab (Rituxan; BR) in mantle cell lymphoma (MCL).

William G. Wierda, MD, PhD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, discusses the evolving treatment paradigm in chronic lymphocytic leukemia and ongoing trials looking at novel approaches.

Curtis A. Pettaway, MD, discusses the need to include the genomic data of African American, Asian, and Hispanic men with prostate cancer in national registries.

William G. Wierda, MD, PhD, discusses the use of CD19-targeted CAR T-cell therapy in the treatment of patients with chronic lymphocytic leukemia.

Robert L. Coleman, MD, FACOG, FACS, discusses what makes veliparib a unique agent in high-grade serous ovarian cancer.

William G. Wierda, MD, PhD, discusses the role of the rituximab biosimilar in the chronic lymphocytic leukemia treatment paradigm.

Neil D. Gross, MD, FACS, discusses a phase II study of neoadjuvant cemiplimab in patients with stage III/IV cutaneous squamous cell carcinoma of the head and neck.

Robert L. Coleman, MD, FACOG, FACS, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of immunotherapy in patients with cervical cancer.

Michael Wang, MD, discusses the toxicity profiles of the BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma.

Naoto Tada Ueno, MD, PhD, FACP, discusses the diagnosis and treatment of patients with inflammatory breast cancer and highlights the biggest challenges in both diagnosing and treating this patient population.

Michael Wang, MD, discusses data from a phase I/II study looking at the use a triplet regimen of vorinostat, cladribine, and rituximab in patients with newly diagnosed mantle cell lymphoma.

Michael Wang, MD, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma.

Eric Jonasch, MD, on how understanding features within the tumor microenvironment and mutated epigenetic modifying genes may provide insight on prognosis or treatment strategies in renal cell carcinoma.

Michael Wang, MD, discusses resistance to CAR T-cell therapy and the next steps to overcoming this challenge in treatment for mantle cell lymphoma.

Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the ongoing phase I/II trial of tagraxofusp (SL-401; Elzonris) in patients with intermediate- or high-risk relapsed/refractory myelofibrosis.

Jennifer K. Litton, MD, associate professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the potential advantage of using biosimilars in oncology.

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses encouraging trial findings in metastatic colorectal cancer (mCRC).

Jorge Cortes, MD, discusses frontline advances, discontinuation, and remaining challenges in the chronic myeloid leukemia paradigm.

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the implications of the NILE trial in non–small cell lung cancer (NSCLC).

Sattva Neelapu, MD, discusses the use of CAR T-cell therapy in the third-line setting for patients with large B-cell lymphoma.

Elias Jabbour, MD, highlights the evolving armamentarium and next steps in the treatment paradigm for acute myeloid leukemia.

Michael Wang, MD, provides insight on recent advances in mantle cell lymphoma as well as research efforts for patients with a high risk of relapse.

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the benefits of liquid biopsy compared with standard tissue in lung cancer.

Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics, medical director of the Institute for Personalized Cancer Therapy, and a professor in the Divisions of Cancer Medicine and Surgery at The University of Texas MD Anderson Cancer Center, discusses the activity of the combination of telaglenastat (CB-839) and cabozantinib (Cabometyx) in heavily pretreated patients with metastatic renal cell carcinoma (mRCC).

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the pace of progress in mantle cell lymphoma (MCL).

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action of tisotumab vedotin (HuMax-TF-ADC) in patients with cervical cancer.

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, discusses distinguishing features of the Guardant360 assay in non–small cell lung cancer (NSCLC).

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses challenges in treating patients with relapsed/refractory mantle cell lymphoma (MCL).

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the correlation between tumor sidedness and biomarkers in colorectal cancer.